Gallant

Gallant Therapeutics Adds Animal Health Executive Aaron Schacht to Board of Directors

Retrieved on: 
Tuesday, February 6, 2024
Gallant, SAN, Growth, Eli Lilly and Company, Eli Lilly, Research, Kindred, FDA, Biotechnology, Disease, Therapy, Boehringer Ingelheim, Novartis, DVM, Health, Pet, Synthetic biology

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the addition of Aaron Schacht to its Board of Directors.

Key Points: 
  • SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the addition of Aaron Schacht to its Board of Directors.
  • "The field of animal health is hungry for innovative solutions to address our pets' health concerns,” said Aaron Schacht.
  • Mr. Schacht led several strategic acquisitions, including Bayer Animal Health, Aratana Therapeutics, and Kindred Biosciences.
  • Additionally, he integrated R&D capabilities and pipelines from Novartis Animal Health, Boehringer Ingelheim pet vaccines, Bayer Animal Health, Aratana, Prevtec, and Kindred.

Gallant Therapeutics Raises Over $15 Million in Series A Funding to Advance Pipeline of "Off-the-Shelf" Stem Cell Therapies for Pets

Retrieved on: 
Monday, January 8, 2024
Pet, Cat, FDA, Conditional sentence, Health, Disease, Microsoft Exchange Server, SAN, Therapy, Dog, Chronic kidney disease, DVM, FCGS, Stem cell, OA, Veterinary medicine, Growth, Gallant, CKD, Pharmaceutical industry

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the successful completion of its Series A financing, securing over $15 million.

Key Points: 
  • SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the successful completion of its Series A financing, securing over $15 million.
  • The successful funding round will enable Gallant to accelerate the development of its pipeline of potentially first-in-class allogeneic stem cell therapeutics, focusing on achieving conditional FDA approval for its leading therapeutic candidate targeting FCGS, a deadly disease with a high unmet medical need.
  • “We have made unprecedented progress this past year, hitting significant clinical, regulatory, and manufacturing milestones,” said Linda Black, DVM, Ph.D., CEO of Gallant Therapeutics.
  • This series A funding represents a crucial step toward Gallant’s vision of bringing "off-the-shelf" stem cell therapies to veterinary clinics worldwide.

Gallant Therapeutics Announces Launch of JEDI Pivotal Study for First Allogeneic Stem Cell Therapy Targeting Feline Chronic Gingivostomatitis

Retrieved on: 
Wednesday, December 6, 2023
Drooling, Quality of life, Cat, Pet, FDA, B cell, Weight loss, Regenerative medicine, Disease, JEDI, SAN, Mouth, Therapy, DVM, Socialization, FCGS, Death, Veterinary medicine, SVP, Gallant, Safety, Argyreia nervosa

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Gallant Therapeutics, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the launch of a pivotal study to evaluate the safety and efficacy of its novel allogeneic stem cell therapy candidate to support FDA conditional approval in cats with refractory feline chronic gingivostomatitis (FCGS), the JEDI study.

Key Points: 
  • SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the launch of a pivotal study to evaluate the safety and efficacy of its novel allogeneic stem cell therapy candidate to support FDA conditional approval in cats with refractory feline chronic gingivostomatitis (FCGS), the JEDI study .
  • More than 50% of these cats do not respond to therapy (are refractory) and are euthanized or die.
  • In pilot studies1, Gallant’s investigational stem cell therapy has been demonstrated effective for refractory FCGS, improving painful lesions and quality of life, allowing these cats to live longer and healthier lives.
  • The multicenter pivotal JEDI study includes veterinary dental specialist sites across the United States and is currently enrolling cats under an FDA-concurred protocol.

Ethos Discovery and Gallant Therapeutics Collaborate on Study Evaluating Gallant’s Stem Cell Therapy in Pugs with Necrotizing Meningoencephalitis (NME), also referred to as Pug Dog Encephalitis (PDE)

Retrieved on: 
Tuesday, October 3, 2023
Ethos, Linda, Necrotizing meningoencephalitis, Seizure, Human, Survival, Brain, Research, Brain damage, Inflammation, Multiple sclerosis, Doctor of Philosophy, Neck, Microsoft Exchange Server, Back pain, Discovery, HIV disease progression rates, T-cell receptor excision circles, SAN, Lethargy, DSM-IV codes, Dog, Blood, Pet, Simons, Steroid, Genetic testing, Cat, Diagnosis, B cell, Therapy, PDE, Phenotype, Encephalitis, DVM, NME, Gallant, Disease, Neurology, Pharmaceutical industry, Medical imaging

Within 24 hours, Walter was diagnosed with pug dog encephalitis (PDE), a common name for necrotizing meningoencephalitis (NME) because it occurs most commonly in that breed.

Key Points: 
  • Within 24 hours, Walter was diagnosed with pug dog encephalitis (PDE), a common name for necrotizing meningoencephalitis (NME) because it occurs most commonly in that breed.
  • Despite aggressive therapy with steroids, immunosuppressants, and anti-seizure medications, Walter died within 24 hours of his diagnosis.
  • In this third study in the program, Ethos Discovery and Gallant Therapeutics are investigating treatment with Gallant’s MSCs in pugs previously screened for NME.
  • To learn more about enrolling your pug in the study, please visit: https://www.ethosdiscovery.org/clinical-study/necrotizing-meningoencepha....

Gallant Capital Partners Invests in Cybersecurity Firms DynTek and rSolutions to Support Growth and Innovation

Retrieved on: 
Wednesday, August 16, 2023
Royal Bank of Canada, Partnership, Optimism, MML Capital Partners, MSSP, Information security operations center, CDW, Kerr, Organization, Security company, Growth, Management, Risk management, Gallant

IRVINE, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Gallant Capital Partners (“Gallant”), a Los Angeles-based investment firm, announced that it has completed a strategic growth investment in DynTek, Inc. (“DynTek”), a US-based professional IT services, cybersecurity, and risk management organization, and rSolutions Corporation (“rSolutions”), a Canadian-based cybersecurity firm.

Key Points: 
  • IRVINE, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Gallant Capital Partners (“Gallant”), a Los Angeles-based investment firm, announced that it has completed a strategic growth investment in DynTek, Inc. (“DynTek”), a US-based professional IT services, cybersecurity, and risk management organization, and rSolutions Corporation (“rSolutions”), a Canadian-based cybersecurity firm.
  • Gallant’s investment in both companies will support accretive growth through further innovation and development of technical offerings and cybersecurity services, operational enhancements that drive customer experience, and strategic acquisitions.
  • This represents the first investment made out of Gallant’s second fund, Gallant Capital Partners II.
  • “I’m looking forward to embarking on this new chapter as CEO and working with the teams at DynTek, rSolutions, and Gallant,” stated Mr. Kerr.

Gallant Capital Partners Invests in Cybersecurity Firms DynTek and rSolutions to Support Growth and Innovation

Retrieved on: 
Wednesday, August 16, 2023
Royal Bank of Canada, Partnership, Optimism, MML Capital Partners, MSSP, Information security operations center, CDW, Organization, Security company, Growth, Management, Gallant

LOS ANGELES, Aug. 15, 2023 /PRNewswire/ - Gallant Capital Partners ("Gallant"), a Los Angeles-based investment firm, announced that it has completed a strategic growth investment in DynTek, Inc. ("DynTek"), a US-based professional IT services, cybersecurity, and risk management organization, and rSolutions Corporation ("rSolutions"), a Canadian-based cybersecurity firm.

Key Points: 
  • LOS ANGELES, Aug. 15, 2023 /PRNewswire/ - Gallant Capital Partners ("Gallant"), a Los Angeles-based investment firm, announced that it has completed a strategic growth investment in DynTek, Inc. ("DynTek"), a US-based professional IT services, cybersecurity, and risk management organization, and rSolutions Corporation ("rSolutions"), a Canadian-based cybersecurity firm.
  • Gallant's investment in both companies will support accretive growth through further innovation and development of technical offerings and cybersecurity services, operational enhancements that drive customer experience, and strategic acquisitions.
  • This represents the first investment made out of Gallant's second fund, Gallant Capital Partners II.
  • As part of the investment, Gallant will unify both organizations under a single leadership structure and investment umbrella.

Lightning Step Divests AVA Billing & Consulting, Reinforcing Focus on Core Behavioral Health Software Solutions

Retrieved on: 
Thursday, June 1, 2023
Mental Health, Health, Technology, Hospitals, Practice Management, Health Technology, Software, Lightning, Ava Bill Martin Memorial Airport, RCM, Sale, Capital, AVA, Growth, Gallant, Risk management

The divestiture of AVA enables Lightning Step to continue its rapid growth trajectory and accelerates the expansion of its all-in-one behavioral healthcare software platform.

Key Points: 
  • The divestiture of AVA enables Lightning Step to continue its rapid growth trajectory and accelerates the expansion of its all-in-one behavioral healthcare software platform.
  • Lightning Step acquired AVA in 2019, and under Lightning Step’s ownership, AVA evolved into an industry-leading full-service RCM solution trusted by many behavioral healthcare facilities and treatment providers nationwide.
  • "Since acquiring AVA in 2019, Lightning Step has worked diligently to grow AVA from its infancy to its current status as a leading RCM solution," said Kirk Monroe, CEO of Lightning Step.
  • By selling AVA, Lightning Step is reinforcing its focus on building a suite of innovative and automated all-in-one behavioral healthcare solutions.

Gallant Capital Invests in Lightning Step to Support Growth

Retrieved on: 
Thursday, November 17, 2022
Mental Health, Health, Technology, Practice Management, Health Technology, Software, General Health, Partnership, Lightning, Ava Bill Martin Memorial Airport, Gallant, EMR, Growth, APriori Capital Partners, Patient, Risk management

Gallant Capital Partners (Gallant), a Los Angeles-based investment firm, announced that it has completed a strategic growth investment in Lightning Step, a rapidly-growing enterprise software provider purpose-built for the behavioral health industry.

Key Points: 
  • Gallant Capital Partners (Gallant), a Los Angeles-based investment firm, announced that it has completed a strategic growth investment in Lightning Step, a rapidly-growing enterprise software provider purpose-built for the behavioral health industry.
  • Gallants investment, augmented with its operational resources, will serve as a catalyst to propel Lightning Step into the leading EMR provider to the behavioral health industry, said Kirk Monroe, CEO of Lightning Step.
  • We are thrilled to be in partnership with the entire Lightning Step team and look forward to contributing to the companys continued growth.
  • Gallant Capital Partners is a private equity firm that invests in technology, business services, and industrial companies.

Pro-Vac Completes Acquisition of Vac-One

Retrieved on: 
Monday, November 7, 2022
Residential Building & Real Estate, Commercial Building & Real Estate, Urban Planning, Manufacturing, Construction & Property, Building Systems, Architecture, Oil, Gas, Steel, Energy, Chemicals, Plastics, Industry, CEO, Growth, CCTV, Gallant, Renewable energy, Fine chemical

The combination will enable Pro-Vac to rapidly expand its subsurface infrastructure service offering across a national footprint.

Key Points: 
  • The combination will enable Pro-Vac to rapidly expand its subsurface infrastructure service offering across a national footprint.
  • We are incredibly excited to further grow Pro-Vac in combination with Vac-One, Graham Gill, CEO of Pro-Vac, added.
  • Enhancing Vac-Ones current service offerings with Pro-Vacs platform of diversified subsurface infrastructure services will immediately benefit Vac-Ones existing customer base.
  • The ability to leverage the combined platforms capabilities will provide our customers with the most comprehensive set of infrastructure services in the market.

Jayson Gallant Moves Up to Vice President of Strategic Partnerships at Ametros

Retrieved on: 
Thursday, October 6, 2022
Professional Services, Health, Insurance, Health Insurance, Human Resources, Finance, Consulting, Gallant, Strategic partnership, Insurance, Marketing, Advocates for Injured Workers, CMS, Industry, Research, Â, Multimedia, Policy, Assumption University, Management

Ametros, which helps people manage their medical funds following insurance settlements, has promoted Jayson Gallant to Vice President of Strategic Partnerships.

Key Points: 
  • Ametros, which helps people manage their medical funds following insurance settlements, has promoted Jayson Gallant to Vice President of Strategic Partnerships.
  • Gallant joined the company over six years ago and most recently held the position of Senior Strategic Account Executive.
  • View the full release here: https://www.businesswire.com/news/home/20221006005065/en/
    Ametros, the leader in post-settlement medical funds administration, has promoted Jayson Gallant to Vice President of Strategic Partnerships.
  • In addition, Gallant works with Ametros industry partners and is involved in product development and research.